Antidepressive effect of mirtazapine in post-myocardial infarction depression is associated with soluble TNF-R1 increase: Data from the MIND-IT

Neuropsychobiology

Volumn 63, Issue 3, 2011, Pages 169-176

  Tulner, D M ^a   Smith, O R F ^f   Schins, A ^b   De Jonge, P ^c   Quere, M ^a   Delanghe, J R ^g   Crijns, H J ^b   Den Boer, J A ^c   Korf, J ^c   Honig, A ^d,e  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d St Lucas Andreas Hospital   (Netherlands)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

^f UNIVERSITY OF BERGEN   (Norway)

^g GHENT UNIVERSITY   (Belgium)

Author keywords

Depression; Inflammation; Mirtazapine; Myocardial infarction

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MIRTAZAPINE; NEOPTERIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BODY MASS; CORONARY ARTERY BYPASS SURGERY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HEART INFARCTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIANSERIN; MIDDLE AGED; MYOCARDIAL INFARCTION; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I;

EID: 78651226939     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321624     Document Type: Article

References (42)

1. Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, Fauerbach JA, Bush DE, Ziegelstein RC: Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med 2006;21:30-38.
2. Carney RM, Blumenthal JA, Freedland KE, Youngblood M, Veith RC, Burg MM, Cornell C, Saab PG, Kaufmann P, Czajkowski SM, Jaffe AS, ENRICHD Investigators: Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom Med 2004;66:466-474. (Pubitemid 38971239)
3. Glassman AH, Bigger JT, Gaffney M, Shapiro PA, Swenson JR: Onset of major depression associated with acute coronary syndromes: relationship of onset, major depressive disorder history, and episode severity to sertraline benefit. Arch Gen Psychiatry 2006;63:283-288. (Pubitemid 43345352)
4. Honig A, Kuyper AM, Schene AH, van Melle JP, de Jonge P, Tulner DM, Schins A, Crijns HJGM, Kuijpers P, Vossen H, Lousberg R, Ormel J, MIND-IT Investigators: Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med 2007;69:606-613. (Pubitemid 47463817)
5. Lespérance F, Frasure-Smith N, Koszycki D, Laliberté MA, van Zyl LT, Baker B: Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007;24:297:367-379.
6. De Jonge P, Honig A, van Melle JP, Schene AH, Kuijper AMG, Tulner D, Schins A, Ormel J, MIND-IT Investigators: Incomplete response to treatment for depression following myocardial infarction is associated with subsequent cardiac events. Am J Psychiatry 2007;164:1371-1378. (Pubitemid 47461137)
7. Dantzer R, Capuron L, Irwin MR, Miller AH, Ollat H, Perry VH, Rousey S, Yirmiya R: Identification and treatment of symptoms associated with inflammation in medically ill patients. Psychoneuroendocrinology 2008;33:18-29.
8. Jiang Y, Deacon R, Anthony DC, Campbell SJ: Inhibition of peripheral TNF can block the malaise associated with CNS inflammatory diseases. Neurobiol Dis 2008;32:125-132.
9. Yirmiya R, Weidenfeld J, Pollak Y, Morag M, Morag A, Avitsur R, Barak O, Reichenberg A, Cohen E, Shavit Y, Ovadia H: Cytokines, 'depression due to a general medical condition' and antidepressant drugs;in Dantzer R, Wollmann EE, Yirmiya (eds): Illness, Cytokines, and Depression. New York, Kluwer Academic/Plenum Publishers, pp 283-316.
10. Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, Avitsur R, Shavit Y, Ovadia H, Weidenfeld J, Morag A, Newman ME, Pollmächer T: Illness, cytokines, and depression. Ann NY Acad Sci 2000;917:478-487.
11. O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG: Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007;41:326-331. (Pubitemid 44854992)
12. Schins A, Tulner D, Lousberg R, Kenis G, Delanghe J, Crijns HJ, Grauls G, Stassen F, Maes M, Honig A: Inflammatory markers in depressed post-myocardial infarction patients. J Psychiatr Res 2005;39:137-144.
13. KrausT, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmacher T: Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002;35:220-225. (Pubitemid 36061311)
14. Hinze-Selch D, Schuld A, Kraus T, Uhr M, Haack M, Pollmacher T: Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 2000;23:13-19.
15. Parissis JT, Adamopoulos S, Rigas A, Kostakis Gl, Karatzas D, Venetsanou K, Kremastinos DT: Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am J Cardiol 2004;94:1326-1328. (Pubitemid 39469963)
16. Ferketich AK, Ferguson JP, Binkley PF: Depressive symptoms and inflammation among heart failure patients. Am Heart J 2005;150:132-136. (Pubitemid 41097440)
17. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E: Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-2153. (Pubitemid 30253042)
18. McCoy MK, Tansey MG: TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008;5:45.
19. Chadwick W, Magnus T, Martin B, Keselman A, Mattson MP, Maudsley S: Targeting TNF-alpha receptors for neurotherapeutics. Trends Neurosci 2008;31:504-511.
20. Bemelmans MH, van Tits LJ, Buurman WA: Tumor necrosis factor: function, release and clearance. Crit Rev Immunol 1996;16:1-11. (Pubitemid 26239999)
21. MacEwan DJ: TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 2002;14:477-492.
22. Van Haelst PL, Liem A, van Boven AJ, Veeger NJ, van Veldhuisen DJ, Tervaert JW, Gans RO, Zijlstra F: Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction. Am J Cardiol 2003;92:1201-1203. (Pubitemid 37377833)
23. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-1772. (Pubitemid 30213096)
24. Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, Cicchitelli G, Olivares A, Parrinello G, Percoco G., Guardigli G, Mele D, Pirani R, Ferrari R: Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation 2005;111:863-870. (Pubitemid 40279887)
25. Widner B, Laich A, Sperner-Unterweger B, Ledochowski M, Fuchs D: Neopterin production, tryptophan degradation, and mental depression - What is the link? Brain Behav Immun 2002;16:590-595.
26. Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, Gedrich K, Kloiber S, Lucae S, Ising M, Uhr M, Holsboer F, Pollmächer T: Depression, comorbidities and the TNF-α system. Eur Psychiatry 2008;23:421-429.
27. Friebe A, Schwarz MJ, Schmid-Wendtner M, Volkenandt M, Schmidt F, Horn M, Janssen G, Schaefer M: Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma. J Immunother 2007;30:333-337. (Pubitemid 46586649)
28. Moorman AJ, Mozaffarian D, Wilkinson CW, Lawler RL, McDonald GB, Crane BA, Spertus JA, Russo JE, Stempien-Otero AS, Sullivan MD, Levy WC: In patients with heart failure elevated soluble TNF-receptor 1 is associated with higher risk of depression. J Card Fail 2007;13:738-743.
29. Gebhardt S, Heiser P, Fischer S, Schneyer T, Krieg JC, Vedde H: Relationships among endocrine and signaling-related responses to antidepressants in human monocytic U-937 blood cells: analysis of factors and response patterns. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1682-1687.
30. Boer T: The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57(suppl 4):19-25.
31. Baron RM, Kenny DA: The moderator-mediator variable distinction in social psychological research: conceptual, strategic and statistical considerations. J Pers Soc Psychol 1986;51:1173-1182.
32. Thase M: Redefining antidepressant efficacy toward long-term recovery. J Clin Psychiatry 1999;60(suppl 6):15-19.
33. Kornstein SG: Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study. Expert Rev Neurother 2008;8:737-742.
34. Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, Costa GM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther 2009;86:527-532.
35. Himmerich H, Binder EB, Kunzel HE, Schuld A, Lucae S, Uhr M, Pollmacher T, Holsboer F, Ising M: Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol Psychiatry 2006;60:882-888. (Pubitemid 44527894)
36. Pan W, Kastin AJ: Tumor necrosis factor and stroke: role of the blood-brain barrier. Prog Neurobiol 2007;83:363-374. (Pubitemid 350116341)
37. Levine SJ: Molecular mechanisms of soluble cytokine receptor generation. J Biol Chem 2008;283:14177-14181.
38. Pan W, Kastin AJ: Upregulation of the transport system for TNF-α at the blood-brain barrier. Arch Physiol Biochem 2001;109:350-353. (Pubitemid 35216881)
39. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M: Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression, a prospective study. J Psychiatr Res 2001;35:83-94. (Pubitemid 32506751)
40. Reynolds JL, Ignatowski TA, Sud R, Spengler RN: An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission. Neuroscience 2005;133:519-531. (Pubitemid 40726218)
41. Taylor JM, Pollard JD: Soluble TNFR1 inhibits the development of experimental autoimmune neuritis by modulating blood-nervebarrier permeability and inflammation. J Neuroimmunol 2007;183:118-124. (Pubitemid 46204916)
42. Tulner DM, Smith ORF, de Jonge P, Van Melle JP, Slomp J, Storm H, Quere M, den Boer JA, Honig A, Korf J: Circulating cerebral S100B is associated with depressive symptoms following myocardial infarction. Neuropsychobiology 2009;59:87-95.